Nykredit A S Purchases Shares of 35,795 Insulet Corporation $PODD

Nykredit A S acquired a new position in shares of Insulet Corporation (NASDAQ:PODD) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 35,795 shares of the medical instruments supplier’s stock, valued at approximately $5,450,000. Nykredit A S owned about 0.05% of Insulet at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of the company. Larson Financial Group LLC grew its position in Insulet by 114.6% during the 4th quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock worth $25,000 after acquiring an additional 47 shares during the last quarter. University of Texas Texas AM Investment Management Co. bought a new position in Insulet in the 4th quarter valued at $26,000. Elyxium Wealth LLC bought a new position in Insulet in the 4th quarter valued at $28,000. DV Equities LLC acquired a new position in Insulet in the fourth quarter worth $28,000. Finally, Mcguire Capital Advisors Inc. acquired a new position in Insulet in the fourth quarter worth $29,000.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on PODD. UBS Group lowered their target price on Insulet from $174.00 to $150.00 and set a “neutral” rating for the company in a research note on Thursday, August 6th. Weiss Ratings downgraded shares of Insulet from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Wednesday, June 24th. Oppenheimer lowered shares of Insulet from an “outperform” rating to a “market perform” rating in a report on Wednesday, August 5th. Citigroup raised their price objective on shares of Insulet from $165.00 to $172.00 and gave the company a “neutral” rating in a research report on Wednesday, July 8th. Finally, BTIG Research downgraded shares of Insulet from a “buy” rating to a “neutral” rating in a research note on Thursday, August 6th. Fourteen analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, Insulet has a consensus rating of “Hold” and an average price target of $195.40.

Insulet Stock Performance

Shares of PODD opened at $147.48 on Monday. The stock’s fifty day simple moving average is $154.45 and its 200-day simple moving average is $177.27. The firm has a market capitalization of $10.23 billion, a PE ratio of 27.57, a price-to-earnings-growth ratio of 1.16 and a beta of 1.08. Insulet Corporation has a 12-month low of $126.40 and a 12-month high of $354.88. The company has a quick ratio of 1.83, a current ratio of 2.48 and a debt-to-equity ratio of 0.65.

Insulet (NASDAQ:PODD) last announced its quarterly earnings data on Wednesday, August 5th. The medical instruments supplier reported $1.66 EPS for the quarter, topping analysts’ consensus estimates of $1.47 by $0.19. The firm had revenue of $801.70 million during the quarter, compared to analyst estimates of $787.39 million. Insulet had a return on equity of 29.29% and a net margin of 12.29%.The company’s revenue was up 23.5% on a year-over-year basis. During the same period last year, the company earned $1.17 earnings per share. Insulet has set its FY 2026 guidance at 6.460- EPS. As a group, research analysts predict that Insulet Corporation will post 6.51 earnings per share for the current year.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.